1
|
Abstract
Biologic drugs have revolutionized the treatment of certain hematologic, autoimmune, and malignant diseases, but they may place patients at risk for reactivation or acquisition of tuberculosis. This risk is highest with the tumor necrosis factor-alpha (TNF-α) inhibitors. Amongst this class of drugs, the monoclonal antibodies (infliximab, adalimumab, golimumab) and antibody fragment (certolizumab) carry an increased risk compared to the soluble receptor fusion molecule, etanercept. Treatment of latent TB is critical to decrease the risk of reactivation. Data continues to emerge regarding tuberculosis risk associated with novel biologics targeting cytokines involved in tuberculosis control.
Collapse
|
2
|
Boyko OV, Choroshilova II, Petrov SV, Melnikov MV, Boyko AN. [Changes in the quality of life in patients with multiple sclerosis treated with ocrelizumab]. Zh Nevrol Psikhiatr Im S S Korsakova 2020; 119:120-127. [PMID: 31934997 DOI: 10.17116/jnevro201911910120] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
AIM To study the quality of life (QoL) in patients with multiple sclerosis (MS) treated with ocrelizumab for at least 12 months. MATERIAL AND METHODS Thirty-eight patients were observed, including 13 with primary progressive MS (PPMS), 15 with highly active relapsing-remitting MS (HAMS) and 10 with secondary progressive MS (SPMS) with relapses. QoL was studied using unspecific SF-36 and MS-specific MusiQoL questionnaires. Depression and fatigue were assessed with the Beck Depression Scale (BDS) and the Modified Fatigue Impact Scale (MFIS). RESULTS AND CONCLUSION Basic characteristics of QoL indexes of the patients were similar to those previously reported for these MS variants. After 6 and 12 months, a significant increase in the indexes of the majority of SF-36 and MusiQoL scales was identified that shows a significant improvement in both physical and psychological domains of QoL. The significant and rapid decrease in depression severity after 6-month treatment with ocrelizumab may at least in part be associated with improvement of indexes of vitality, general health, social relations and the total QoL score.
Collapse
Affiliation(s)
- O V Boyko
- Pirogov's Russian Science Research Medical University, Moscow, Russia; Yusupov Hospital, 'Neuro-Clinica', Moscow, Russia; Federal Center of Cerebrovascular Pathology and Stoke, Moscow, Russia
| | | | - S V Petrov
- Yusupov Hospital, 'Neuro-Clinica', Moscow, Russia
| | - M V Melnikov
- Pirogov's Russian Science Research Medical University, Moscow, Russia; Federal Center of Cerebrovascular Pathology and Stoke, Moscow, Russia
| | - A N Boyko
- Pirogov's Russian Science Research Medical University, Moscow, Russia; Yusupov Hospital, 'Neuro-Clinica', Moscow, Russia; Federal Center of Cerebrovascular Pathology and Stoke, Moscow, Russia
| |
Collapse
|
3
|
Evdoshenko E, Stepanova A, Shumilina M, Davydovskaya M, Khachanova N, Neofidov N, Kalinin I, Popova E, Dubchenko E, Pozhidaeva N, Volkov A, Sivertseva S, Prilenskaya A, Malkova N, Korobko D, Vergunova I, Shchur S, Makshakov G. Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia. PLoS One 2019; 14:e0217303. [PMID: 31136608 PMCID: PMC6538157 DOI: 10.1371/journal.pone.0217303] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2018] [Accepted: 05/08/2019] [Indexed: 11/30/2022] Open
Abstract
Background NTZ is approved in Russia for the treatment of highly active relapsing remitting multiple sclerosis and is reimbursed via federal budget program. However, no data about NTZ treatment in Russia and the effect of federal reimbursement have been performed so far. Objective To characterize the population of patients receiving natalizumab and assess the efficacy and risk-management plan (RMP) implementation of NTZ therapy in routine clinical practice in Russia. Methods We analyzed data for 334 patients, who received at least one infusion of NTZ. Relapse rate, MRI activity, NEDA-3 status after 2 years were assessed. Anti-JC virus antibodies status and RMP implementation were evaluated. Drop-out rate and reasons for therapy discontinuation were analyzed. Results Patients switched to natalizumab in Russia are mainly female (63%), with median EDSS score of 3.5 and high disease activity: 93% had at least 1 relapse and 58% had both T1Gd+ and new T2 lesion a year before therapy initiation. Introduction of federal reimbursement allowed patients with less relapses to start therapy with natalizumab. The only predictor of 6-month progression was EDSS score at the baseline of therapy (HR = 2.1375, 95%CI 1.0026–4.5570, p = 0.0492). 82% patients reached NEDA-3 at 24 month of therapy. 25% of patients discontinued NTZ for reasons: tolerability (14.5%), JCV antibody status (61%), and patient’s decision (17%). RMP was implemented in only 36% patients. Conclusion Natalizumab appeared to have high efficacy in Russian clinical practice. Federal reimbursement allowed less active patients to start natalizumab. More efforts should be done to improve RMP implementation.
Collapse
Affiliation(s)
- Evgeniy Evdoshenko
- SPb Center of Multiple Sclerosis and AID (SBIH City Clinical Hospital #31), St. Petersburg, Russia
- * E-mail:
| | - Alexandra Stepanova
- SPb Center of Multiple Sclerosis and AID (SBIH City Clinical Hospital #31), St. Petersburg, Russia
| | - Maria Shumilina
- SPb Center of Multiple Sclerosis and AID (SBIH City Clinical Hospital #31), St. Petersburg, Russia
| | - Maria Davydovskaya
- State Budgetary Institution of Moscow City “Clinical Trials and Healthcare Technology Assessment Scientific-Research Centre of Moscow Department of Healthcare”, Moscow, Russian Federation
- Pirogov Russian National Research Medical University, Moscow, Russia
| | | | - Nikolay Neofidov
- SPb Center of Multiple Sclerosis and AID (SBIH City Clinical Hospital #31), St. Petersburg, Russia
| | - Ivan Kalinin
- SPb Center of Multiple Sclerosis and AID (SBIH City Clinical Hospital #31), St. Petersburg, Russia
| | | | | | | | | | - Stella Sivertseva
- “Medical Sanitary Unit «Neftyanik», Tyumen Multiple Sclerosis Center, Tyumen, Russia
| | - Anna Prilenskaya
- “Medical Sanitary Unit «Neftyanik», Tyumen Multiple Sclerosis Center, Tyumen, Russia
| | - Nadezhda Malkova
- State Novosibirsk Regional Clinical Hospital, Center of MS and other AID of Nervous System, Novosibirsk, Russia
- State Novosibirsk Medical University, Novosibirsk, Russia
| | - Denis Korobko
- State Novosibirsk Regional Clinical Hospital, Center of MS and other AID of Nervous System, Novosibirsk, Russia
| | - Ilona Vergunova
- State Novosibirsk Regional Clinical Hospital, Center of MS and other AID of Nervous System, Novosibirsk, Russia
| | | | - Gleb Makshakov
- SPb Center of Multiple Sclerosis and AID (SBIH City Clinical Hospital #31), St. Petersburg, Russia
| |
Collapse
|
4
|
Davydovskaya MV, Khachanova NV, Evdoshenko EP, Pronin IN, Boiko AN, Zakharova MN, Alifirova VM, Turova EA, Malkova NA, Sivertseva SA, Tsukurova LA, Skoromets AA, Solodun IY. [Recommendations on the algorithms for drug choice and risk management plan in the treatment of patients with remitting multiple sclerosis with natalizumab]. Zh Nevrol Psikhiatr Im S S Korsakova 2017; 116:79-97. [PMID: 28139616 DOI: 10.17116/jnevro201611610279-97] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- M V Davydovskaya
- Pirogov Russian National Research Medical University, Moscow, Russia; Center of Coordination and Clinical Examination of Medical Drugs, Moscow Department of Public Health, Moscow, Russia
| | - N V Khachanova
- Pirogov Russian National Research Medical University, Moscow, Russia; Center of Coordination and Clinical Examination of Medical Drugs, Moscow Department of Public Health, Moscow, Russia
| | - E P Evdoshenko
- Center of Coordination and Clinical Examination of Medical Drugs, Moscow Department of Public Health, Moscow, Russia; City Center of Multiple Sclerosis And Autoimmune Diseases at Hospital #31, Moscow, Russia
| | - I N Pronin
- Burdenko Research Institute of Neurosurgery, Moscow, Russia
| | - A N Boiko
- Pirogov Russian National Research Medical University, Moscow, Russia
| | | | | | - E A Turova
- Siberian Regional Hospital #1, Yekaterinburg, Russia
| | - N A Malkova
- Novosibirsk State Medical University, Novosibirsk, Russia
| | | | - L A Tsukurova
- Research Institute - Ochapovsky Regional Hospital #1, Krasnodar, Russia
| | - A A Skoromets
- Pavlov St. Petersburg State Medical University, St. Petersburg, Russia
| | - I Yu Solodun
- Center of Coordination and Clinical Examination of Medical Drugs, Moscow Department of Public Health, Moscow, Russia
| |
Collapse
|
5
|
Melnikov MV, Belousova OO, Zhetishev RR, Pashenkov МV, Boyko AN. [The influence of catecholamines on Th17-cells in multiple sclerosis]. Zh Nevrol Psikhiatr Im S S Korsakova 2017; 116:16-20. [PMID: 28139606 DOI: 10.17116/jnevro201611610216-20] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
AIM Тo investigate the possible association between clinical characteristics of multiple sclerosis (MS), quantitative and qualitative characteristics of Th17, dopamine and norepinephrine concentrations in the serum in patients with multiple sclerosis (MS). MATERIAL AND METHODS A comprehensive neurological and immunological examination of 43 patients with relapsing-remitting-MS (RR-MS) was performed. All patients were subjected to a standard neurological examination with assessment of the EDSS score. Dopamine and norepinephrine concentrations in serum were measured by enzyme-linked immunosorbent assay (ELISA). Percentage of Th17-cells was determined by flow cytometry. The functional activity of Th17- and Th1-cells was assessed by the production of interleukin-17 (IL-17) and interferon-gamma (IFN-γ), respectively, by peripheral blood mononuclear cells (PBMC) stimulated with microbeads coated with anti-CD3 and anti-CD28-antibodies. RESULTS The percent Th17-cells and cytokine production was significantly higher in MS patients with the exacerbation of disease than in the control group or remission, while the dopamine level was lower. Norepinephrine levels in MS patients in the acute stage and remission were comparable, but nevertheless, reliably lower than in the control group. CONCLUSION The results suggest the inhibitory effect of catecholamines on Th17 cells.
Collapse
Affiliation(s)
- M V Melnikov
- Pirogov Russian National Research Medical University, Moscow, Russia
| | - O O Belousova
- Pirogov Russian National Research Medical University, Moscow, Russia
| | - R R Zhetishev
- Pirogov Russian National Research Medical University, Moscow, Russia
| | | | - A N Boyko
- Pirogov Russian National Research Medical University, Moscow, Russia
| |
Collapse
|
6
|
Boyko AN, Gusev EI. Current algorithms of diagnosis and treatment of multiple sclerosis based on the individual assessment of the patient. Zh Nevrol Psikhiatr Im S S Korsakova 2017; 117:92-106. [DOI: 10.17116/jnevro20171172292-106] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|